13 completed, 6 recruiting, 4 terminated, 3 unknown. 29 Phase 2, 12 Phase 1, 1 Phase 3.
Follow CLL: new trials by email Literature Review of CLL trials Research Report on CLL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI Epcoritamab - CLL, CLL (Chronic Lymphocytic Leukemia) | Phase 2 | Not yet recruiting | University of California, Irvine | 24 | 2026-10-01 | 2026-09-14 |
| Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma BAFF-R CAR-T - DLBCL, CLL | Phase 1 / Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2025-11-29 | 2026-05-13 |
| Study of Epcoritamab as a Consolidation Therapy in CLL/SLL Epcoritamab - CLL/SLL, CLL | Phase 2 | Recruiting | Zulfa Omer | 22 | 2025-08-22 | 2026-01-06 |
| A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. Sonrotoclax, Zanubrutinib - Chronic Lymphocytic Leukemia, CLL | Phase 1 / Phase 2 | Recruiting | BeOne Medicines | 258 | 2025-01-23 | 2026-10-26 |
| Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms Zinc-64 Aspartate - CLL, Solid Tumor, Adult | Phase 1 / Phase 2 | Recruiting | Vector Vitale LLC | 36 | 2024-05-15 | 2026-08-05 |
| Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia CARCIK-CD19 - B-cell NHL, CLL | Phase 1 / Phase 2 | Recruiting | Fondazione Matilde Tettamanti Menotti De Marchi Onlus | 29 | 2023-12-01 | 2024-05-03 |
| Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL Zandelisib, Rituximab, Venetoclax - CLL | Phase 2 | Withdrawn | MEI Pharma, Inc. | 2022-11-22 | 2023-03-16 | |
| A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL. GB261 - B Cell NHL, CLL | Phase 1 / Phase 2 | Unknown | Genor Biopharma Co., Ltd. | 460 | 2021-08-31 | 2023-05-22 |
| CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD. ibrutinib, venetoclax, obinutuzumab, ibrutinib, venetoclax - CLL | Phase 2 | Active not recruiting | Stichting Hemato-Oncologie voor Volwassenen Nederland | 85 | 2020-12-29 | 2021-08-23 |
| Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment Acalabrutinib, Venetoclax - CLL | Phase 2 / Phase 3 | Recruiting | Copenhagen University Hospital, Rigshospitalet | 212 | 2019-10-11 | 2023-12-04 |
| A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine - Malignancy, Non-hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Cyteir Therapeutics, Inc. | 169 | 2019-10-09 | 2024-12-24 |
| Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL TP-0903, TP-0903 and ibrutinib combination therapy - Chronic Lymphocytic Leukemia, CLL | Phase 1 / Phase 2 | Terminated | Sumitomo Pharma America, Inc. | 3 | 2019-06-10 | 2023-11-09 |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies Acalabrutinib, Pembrolizumab - Follicular Lymphoma (FL), CLL | Phase 1 / Phase 2 | Completed | Acerta Pharma BV | 161 | 2015-02-20 | 2026-05-13 |
| A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP) GA101/HDMP - CLL | Phase 1 / Phase 2 | Unknown | University of California, San Diego | 40 | 2014-09-01 | 2023-08-30 |
| Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL) A6 - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Terminated | Ångstrom Pharmaceuticals | 5 | 2014-02-01 | 2016-07-13 |
| Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL Lenalidomide - CLL, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Arbeitsgemeinschaft medikamentoese Tumortherapie | 12 | 2012-06-01 | 2016-05-26 |
| A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide (CY) - Hematologic Malignancy, Leukemia | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 4 | 2012-03-01 | 2025-05-04 |
| Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL Ofatumumab, High-Dose Methylprednisolone, Alemtuzumab - CLL, SLL | Phase 2 | Terminated | Dana-Farber Cancer Institute | 30 | 2011-12-01 | 2023-08-29 |
| Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL) Eltrombopag - CLL, Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 23 | 2010-11-03 | 2023-03-23 |
| Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Revlimid, Rituximab - Chronic Lymphocytic Leukemia, CLL | Phase 2 | Completed | University of California, San Diego | 30 | 2010-08-01 | 2024-08-15 |
Showing 20 of 29. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (17) · Leukemia (10) · Hodgkin Disease (5) · Neoplasms (5) · Lymphoma, Non-Hodgkin (4) · Multiple Myeloma (4) · Hematologic Neoplasms (3) · Lymphoma, Follicular (3) · Lymphoma, Mantle-Cell (3) · Recurrence (3) · Anemia, Aplastic (2) · Lymphoma (2) · Myeloproliferative Disorders (2) · Neoplasm Metastasis (2) · Pancreatic Neoplasms (2)
Hemic and Lymphatic Diseases (22) · Neoplasms by Histologic Type (22) · Hematologic Diseases (21) · Immune System Diseases (21) · Immunoproliferative Disorders (21) · Lymphatic Diseases (21) · Lymphoproliferative Disorders (21) · Pathologic Processes (19) · Pathological Conditions, Signs and Symptoms (19) · Chronic Disease (18) · Disease Attributes (18) · Leukemia, Lymphoid (17) · Neoplasms (17) · Leukemia, B-Cell (16) · Leukemia (10)
Lenalidomide (5) · Rituximab (4) · Cyclophosphamide (3) · Cyclosporine (3) · venetoclax (3) · Alemtuzumab (2) · Granulocyte Colony-Stimulating Factor (2) · Methylprednisolone (2) · Mycophenolic Acid (2) · acalabrutinib (2) · fludarabine (2) · ofatumumab (2) · Acetaminophen (1) · Antilymphocyte Serum (1) · Bendamustine Hydrochloride (1)
M.D. Anderson Cancer Center (3) · Beth Israel Deaconess Medical Center (2) · University of California, San Diego (2) · Acerta Pharma BV (1) · Arbeitsgemeinschaft medikamentoese Tumortherapie (1) · BeOne Medicines (1) · Chronic Lymphocytic Leukemia Research Consortium (1) · Copenhagen University Hospital, Rigshospitalet (1) · Cyteir Therapeutics, Inc. (1) · Dana-Farber Cancer Institute (1) · Fondazione Matilde Tettamanti Menotti De Marchi Onlus (1) · Genor Biopharma Co., Ltd. (1) · Genta Incorporated (1) · Gilead Sciences (1) · Institute of Hematology & Blood Diseases Hospital, China (1)
United States (21) · Australia (2) · China (2) · Denmark (2) · Netherlands (2) · Austria (1) · Brazil (1) · France (1) · Italy (1) · Sweden (1) · Ukraine (1) · United Kingdom (1)
David E Avigan, MD (2) · David F McDermott, MD (2) · Thomas J Kipps, MD, PhD (2) · Alessandra Ferrajoli, M.D. (1) · Andrea Biondi, MD (1) · Arnon Kater, PhD (1) · Carsten U Niemann, MD, PhD (1) · Catherine C Coombs, MD (1) · Danelle F James, M.D. (1) · Dolores Grosso, DNP, CRNP (1) · Grygorii Ursol, MD, PhD (1) · Januario Castro, MD (1) · Jennifer R Brown, MD PhD (1) · Kipps Thomas, MD (1)
PMID 16186597, PMID 21173095, PMID 21725050, PMID 23801633, PMID 26389849, PMID 29358183, PMID 30322319, PMID 37497921, PMID 38393694, PMID 40073834, PMID 41338862
2019 (1)